Sell-the-News Hits MoonLake: Strong Sonelokimab Data Fail to Impress vs. Bimzelx
Strong results matched but did not beat Bimzelx, triggering sell-the-news.
/ 10 items
#MLTX↓
MoonLake’s Sonelokimab Achieves High Response Rates in HS After 12 Months
Sonelokimab shows strong 1-year results in HS, with many patients seeing clear skin, less pain, and better quality of life, with good safety.
MoonLake Gets Major Analyst Boost After “Best-in-Class” FDA Meeting
MoonLake gets FDA support for its HS drug, showing top results. Analysts stay bullish with strong growth potential ahead.
MoonLake Immunotherapeutics Gets Bullish Upgrade: Analyst Sees $40 Target as FDA Path Clears for Sonelokimab in HS
Rothschild Redburn upgrades MoonLake to Buy from Neutral. Sonelokimab's FDA path for HS clears major hurdle; seen as best-in-class contender attractive to big pharma.
MoonLake's Sonelokimab Gets FDA Fast Track for Rare Skin Disease
MoonLake Immunotherapeutics receives FDA Fast Track designation for sonelokimab in palmoplantar pustulosis, accelerating development for this untreated skin condition.
Goldman Sachs Turns Bearish on MoonLake
Goldman Sachs downgraded MoonLake Immunotherapeutics to Sell, citing high approval risks despite progress in Phase 3 trials.